Kornimate/medical-research-clean huggingface dataset:
retrospective study of ibs-d patients previously receiving sbi

Conditions: Diarrhoea Predominant Irritable Bowel Syndrome

Summary: this is a retrospective study designed to gather outcomes data from existing medical charts from patients who have taken enteragam for management of their ibs-d for at least eight weeks. data from two study periods will be collected: (1) the time during which the standard of care (soc) therapy (i.e., prescribed or over-the-counter as well as fda-approved or non-approved agents) that is used immediately prior to prescribing enteragam; and (2) the time during which enteragam is used as therapy.

* the first collection of information (visit 1 - chart report form) will be for the visit at which the soc therapy, utilized immediately before the introduction of enteragam, was initiated. this data point will serve as the baseline for that soc therapy. * the second collection of information (visit 2 - chart report form) will be for the visit at which the original prescription for enteragam was written and the patient was instructed to begin the therapy. captured data will consist of information contained in the patient's chart for a minimum of eight weeks and a maximum of 12 weeks prior to initiation of enteragam therapy. this data point will serve as the baseline for initiation of enteragam therapy. * the third collection point (visit 3 - chart report form) will be at the next patient visit to the clinic - provided that visit is a minimum of eight weeks following initiation of enteragam therapy.

Eligibility criteria:
inclusion criteria: * patient is at least 18 years of age at the initiation of enteragam therapy. * patient has been previously diagnosed with ibs-d by the physician and has undergone at least one course of soc treatment prior to receiving enteragam. * patient has completed a minimum of eight weeks of enteragam therapy for his / her ibs-d. * there is recorded information regarding patient response to soc or enteragam for stool frequency/consistency and abdominal pain exclusion criteria: * patient has not taken enteragam for a minimum of eight weeks or has not used the product according to the directions provided by the prescribing physician. * patient has not consented to the use of their clinical data in this retrospective clinical investigation.

Keywords: ibs-d ibs
the influence of oral vibrational stimulation on cognitive function of elderly individuals

Conditions: Mild Cognitive Impairment

Summary: the purpose of this study is to investigate the effect of oral vibratory stimulus on the brain activity and cognitive function of elderly people with non-dementia subjects (cognitive normal, mild cognitive impairment)

evaluating the effect of oral vibratory stimulus on the brain activity and cognitive function of elderly people with mild cognitive impairment ◇ test design: open-labeled, prospective, pre-post study ○ oral vibratory stimulus: as an optimal algorithm drawn through the first year study, the vibratory stimulus is applied 10 times for 15 days (a 5-minute stimulus is applied two times a day for 10 days, and it is composed of repeated 15-second vibratory and 15-second non-vibratory stimulus with a strength of 3.3v).

Eligibility criteria:
inclusion criteria * a person who has at least 20 natural teeth, including the first molars (including fixed prostheses and implants, excluding removable prostheses) * a person who has systemic health, including controlled hypertension/hypotension and diabetes patients * an elderly person who has been diagnosed with normal cognition or mild cognitive impairment in a neuropsychological test and cerad clinical evaluation (refer to separate inclusion criteria) exclusion criteria * a person who has medical history of nervous system disease * a person who is has ever been allergic to resin * a person who has untreated periodontal disease and/or severely loose teeth * a person who has a medical treatment history of temporomandibular disorders, who has an occurrence of stomatitis once or more per month within the last 6 months, or who currently has stomatitis * a person who is receiving or has received treatment for major mental diseases such as dementia, major depression, or mania based on the dsm-iv diagnosis * a person who has a medical disease that can have a serious effect on cognitive function or is taking related medicine * a person who has a transplant that is electrically or mechanically operated or a cerebrovascular clip or who has claustrophobia so that an mri scan is impossible

Keywords: oral vibrational stimulation cognitive function mild cognitive impairment cognitive normal elderly
the hordaland health study

Conditions: Chronic Disease

Summary: the hordaland health studies (hhs) were conducted in 1992-93 (the homocysteine study) and in 1997-99 (husk). both surveys were conducted as a joint project between the university of bergen, the norwegian health screening service (shus) (now part of the national institute of public health) and the municipal health service in hordaland. the main focus of the studies is on chronic diseases including cardiovascular disease, cancer, osteoporosis, anxiety and depression. some projects focus on psychosocial factors, occupational research, musculoskeletal diseases, urinary incontinence and mapping of drug use. the main purpose of the surveys is to gather information so that disease ultimately can be prevented. approximately 36,000 residents of hordaland county participated in the studies, ca. 18,000 in 1992-93 and ca. 26,000 in 1997-99. about 7,000 of those who participated in the 1992-93 survey also participated in 1997-99.


Eligibility criteria:
inclusion criteria: * born in a specific time-period * from hordaland county * community-dwelling people who were able to come to the study site on their own, and able to fill out questionnaires. exclusion criteria: * not born within the specific time-period * not from hordaland county * institutionalized people * people who were not able to fill out questionnaires
measurement of viral load reduction in the oral cavity after a regimental use of oc toothpaste products

Conditions: Covid19

Summary: sars covid 2 has caused a pandemic of proportions unparalleled in the past 100 years. the virus has an uncanny ability for transmission and as such has been difficult to control. the spread of the virus has affected everything from education, business, politics and survival. while the investigators have learned a great deal in the last 9 months they still face an uncertain day to day existence. health care workers are particularly vulnerable to transmission of this virus because of their close contact with patients. moreover, dentists are particularly vulnerable because the virus is spread via aerosols which are generated quite easily in the dental office putting dentists and their associates at risk. the oral cavity appears to be a likely domain for viral carriage particularly since both taste and smell are hallmark effects of the virus. with these issues at hand it will be of great advantage to have a simple routine oral hygiene method in the effort to reduce the oral viral load. there is some reason to expect that oral hygiene procedures with known anti-microbial effects could have some use in our efforts to reduce or control the oral viral load. with this issue in mind investigators feel that stannous fluoride could modify the virus in such a manner as to effectively reduce the oral viral load.

study will measure reduction of sars-cov-2 levels in the oral cavity after brushing for up to an hour. subject sampling will occur at baseline, 15 min, 30 min, and 60 min

Eligibility criteria:
inclusion criteria: * enrolled subjects between the ages of 18-64 and have tested positive for covid19. exclusion criteria: -
baclofen in the treatment of alcohol dependence with or without alcoholic liver disease

Conditions: Alcoholic Liver Disease; Alcohol Dependence

Summary: to explore the effectiveness and biobehavioural basis of baclofen in improving treatment outcomes for alcohol dependence in people with or without alcoholic cirrhosis in a double-blind randomised placebo-controlled trial.

this is a double-blind randomised placebo-controlled study investigating the efficacy of baclofen for the treatment of alcohol dependence in patients with alcoholic liver disease. medications will be given for 12 weeks, with a further 6 months follow-up. both male and female participants will be recruited to this study. trial patients will be randomised to one of three treatment groups: (1) baclofen 30mg/day (10 mg t.i.d), (2) baclofen 75mg/day (25 mg t.i.d) or (3) placebo (3 matched tabs/day). this study will also include a second, parallel group of patients with alcohol dependence (non alcoholic-liver disease patients) that will undergo the trial protocol as described above. these patients will be randomised according to a separate list into one of three treatment groups: (1) baclofen 30mg/day (10 mg t.i.d), (2) baclofen 75mg/day (25 mg t.i.d) or (3) placebo (3 matched tabs/day).

Eligibility criteria:
inclusion criteria: * ald (for trial group 1), defined as the presence of symptoms and/or signs referable to liver disease with or without cirrhosis, in which alcohol use is considered to play a major aetiological role. alcohol use will have exceeded an average of 60g/day in women and 80g/day in men for \>10 years. * alcohol dependence according to the icd-10 criteria (for both trial 1 and 2) * adequate cognition and english language skills to give valid consent and complete research interviews * willingness to give written informed consent * abstinence from alcohol for between 3 and 21 days * resolution of any clinically evident alcohol withdrawal (ciwa-ar) exclusion criteria: * active major psychological disorder associated with psychosis or significant suicide risk * pregnancy or lactation * concurrent use of any psychotropic medication other than antidepressants * substance use other than nicotine if unstable * clinical evidence of persisting hepatic encephalopathy * pending incarceration * lack of stable housing * active peptic ulcers * unstable diabetes mellitus
establishment of precise nutrition management scheme for patients with prediabetes based on nutrigenomics

Conditions: Prediabetes

Summary: with the aging of population and the change of lifestyle, the prevalence of prediabetes is increasing year by year. nutritional factors are one of the important environmental factors in the occurrence and development of abnormal glucose metabolism. the medical nutritional treatment of diabetes is recommended as the cornerstone of diabetes treatment by various guidelines. with the development of nutrigenomics, it has been found that genes related to the absorption, metabolism, distribution and excretion of various nutrients are related to diabetes. this study intends to conduct precision nutrition intervention for prediabetic patients based on nutritional genes, and evaluate the effectiveness and safety of these nutritional interventions.


Eligibility criteria:
inclusion criteria: 1. ogtt: 6.1 mmol/l ≤ fasting plasma glucose \< 7.0 mmol/l and（or）7.8 mmol/l ≤ 2 hour plasma glucose \< 11.1 mmol/l and (or) 5.7% ≤ hba1c\< 6.5%. 2. 18 ≤ age \<70. exclusion criteria: 1. patients who can be diagnosed with diabetes mellitus. 2. patients applying antidiabetic drugs, glucocorticoids, and other drugs that have an effect on blood glucose. 3. females during pregnancy or lactation. 4. patients with gastrointestinal disorders, psychiatric disorders, autoimmune disorders, tumors, etc. 5. patients with acute cardiovascular and (or) cerebrovascular diseases within 6 months prior to study participation. 6. patients with hepatic dysfunction (alt, ast, or total bilirubin ≥ 2 times the upper limit of normal), renal dysfunction (creatinine \> the upper limit of normal), and cardiac dysfunction (nyha class iii and iv).

Keywords: prediabetes nutrigenomics nutritional intervention
cardiovascular prophylaxis for postmenopausal women

Conditions: Cardiovascular Disease

Summary: the purpose of this study was to examine the effect of 6 months moderate intensity exercise training completed three times per week upon traditional and emerging cardiovascular disease risk factors in postmenopausal women both with and without type 2 diabetes. these risk factors include blood markers associated with increased risk such as cholesterol, insulin, glucose and markers of inflammation plus measures of body fat, heart and lung fitness, vascular stiffness and vascular function. the study hypothesised that moderate intensity exercise training would intervene in the exaggerated risk seen in women following the menopause, especially in those with type 2 diabetes.


Eligibility criteria:
inclusion criteria: * healthy and stable type ii diabetic postmenopausal women (cessation of menstrual periods for 12 months and confirmed with lh/fsh samples) aged 45 - 65 years old for the cross sectional analysis and exercise training study. exclusion criteria: * identified abnormalities during baseline testing. * vigorously active women. * women who are pregnant. * women with serious systemic or psychological disorders (e.g. copd, asthma, clinical depression). * women with known coronary artery disease. * women with significant cardiovascular pathologies and associated medication. * women with type 1 or insulin treated diabetes. * women with diabetes with complications. * women with unstable diabetes or hypertension. * women with any cancer. * women with musculoskeletal impairments or contraindications to exercise.

Keywords: body composition endothelial function lipoprotein profile inflammatory markers aerobic capacity thrombotic markers arterial stiffness cardiac function traditional and emerging cardiovascular disease risk factors
cbt depression intervention for co-occurring chronic headache

Conditions: Depression; Headaches Chronic; Migraine Disorders

Summary: having co-occurring depression and chronic headaches is challenging and can greatly impact one's professional, personal, family, and social life. people living with chronic headaches are often at a greater risk of having comorbid psychiatric disorders (depression, anxiety), reduced quality of life, and impaired functioning because of under-diagnosis, misdiagnosis or under-treatment of both chronic conditions. this study is a pilot clinical trial that will compare the effectiveness of a brief cognitive-behavior therapy (cbt) depression intervention to a care as usual (control) group. the aim of the study is to determine how well the cbt intervention will reduce the frequency, severity and level of disability of both the headaches and depression symptoms.

study locations: (a) university of georgia college of education in athens, ga (b) henry ford hospital - main campus in detroit, mi. * for the mi participants, you must be willing to travel to detroit for the intervention if you choose to participate and are assigned to the treatment group. \*\*please contact me with any questions about the study.\*\* background: this research focuses on emphasizing alternative treatment approaches to underserved and marginalized groups. this study is a randomized pilot intervention to treat a community sample with co-occurring depression and chronic pain (i.e. headaches/migraines) - since they are at an increased risk for impaired functioning, comorbid psychiatric disorders and reduced quality of life.

Eligibility criteria:
inclusion criteria: * 18-75 years of age \& living in ga or mi; * a phq-9 score ≥5; and * have frequent migraines and/or moderate to severe headaches = 10 or more headache days per month for the past 3 months * may or may not be taking headache/migraine medication so long as still meet other criteria * \*\* for mi participants: must be willing \& able to come to detroit campus for the intervention (4 weeks in a row) exclusion criteria: * outside of 18-75 year old age range; * do not live in ga or mi * unable or unwilling to drive to campus location for the 4 sessions (treatment group only) * do not have both conditions of depression and frequent/near-chronic headaches * active suicidal ideation (detailed plan and/or access to lethal means) or suicide attempts within the past 60 days.

Keywords: chronic headaches, migraines, depression
innovative delivery of evidence based psychotherapy to women with military sexual trauma

Conditions: PTSD; Stress Disorders, Post - Traumatic; Anxiety Disorders; Mental Disorders; Stress Disorders, Traumatic

Summary: the purpose of this study is to determine whether a scientifically validated treatment for posttraumatic stress disorder (ptsd) called prolonged exposure (pe) can be delivered effectively to veterans with military sexual trauma (mst) related ptsd using videoconferencing technology, which allows a therapist and patient who are not in the same room as one another to communicate. the investigators are interested in learning if this form of mental health service delivery is an acceptable alternative to traditional face-to-face therapy delivered with the therapist in the same room as the patient. this study is being conducted at the charleston va medical center and surrounding community-based outpatient clinics (cbocs), and will involve approximately 100 female participants.

the purpose of this project is to test, using mixed qualitative and quantitative assessment strategies, the efficacy of pe delivered via home-based telehealth (pe-hbt) versus pe delivered via standard service delivery (pe-sd) using a randomized, between groups, repeated measures design. objective 1: to compare, at post, 3 and 6-month follow-up, whether pe-hbt is superior to pe-sd across critical clinical and quality of life outcomes (i.e., ptsd, depression, quality of life) due to increased pe 'dosing' that results from improved session attendance and reduced attrition. hypothesis 1: in intent-to-treat analyses, pe-hbt will be more effective than pe-sd at improving clinical and quality of life outcomes at post, 3, and 6-month follow-up; improvement will correlate with session attendance, which will be higher in pe-hbt. objective 2: to compare at post-intervention whether pe-hbt is superior to pe-sd across critical process outcomes (e.g., session attendance, satisfaction, and treatment adherence). hypothesis 2: pe-hbt will yield better process outcomes than pe-sd post-intervention. exploratory aims: (1) to determine if treatment adherence and other process variables mediate the relationship between treatment condition and clinical and quality of life outcomes as noted in objective 1; and (2) to use qualitative interviewing methods to obtain data on veterans' reactions, preferences, difficulties, and suggestions for mst services.

Eligibility criteria:
inclusion criteria: 1. mst-related index event 2. diagnosis of ptsd-related mst 3. female exclusion criteria: 1. having a household member of spouse who is already enrolled in the study 2. active psychosis or dementia 3. suicidal and/or homicidal ideation with clear intent 4. current substance dependence 5. concurrent enrollment in another clinical trial for ptsd or depression 6. unwilling to make regular appointments (note that if the participant has medical/transportation barriers that render her unable to make set appointments, this is not grounds for exclusion).

Keywords: military health service delivery telepsychology prolonged exposure off-duty activity of military personnel
parisk: validation of imaging techniques

Conditions: Stroke; Atherosclerosis

Summary: the possibility of the identification of the risk of rupture of a carotid plaque will have tremendous impact in clinical decision making. firstly, in symptomatic patients with a 30-69% stenosis, who are currently not operated upon according to the current guidelines, identification of the risk of rupture plaque could identify patients who have a high risk of recurrent stroke, and would benefit of carotid intervention, such as endarterectomy or stent placement. this could potentially prevent a substantial number of strokes. secondly, in all symptomatic patients with a 70-99% stenosis carotid intervention should be considered, according to the guidelines. however, only one out of six patients with a 70-99% stenosis benefits from a carotid intervention. identification of patients with a high risk of a recurrent stroke would reduce the number of unnecessary interventions substantially. the main objective is to show whether imaging characteristics assessed at baseline can predict clinical events in patients with a 30-69 % symptomatic carotid stenosis.


Eligibility criteria:
inclusion criteria: * neurological symptoms due to ischemia in the carotid artery territory as diagnosed by their neurologist based on anamneses, physical examination and brain imaging (ct or mri) * carotid artery stenosis \< 70% (upper cut-off value is based on the nascet criteria, the lower cut-off value is an atherosclerotic plaque with a thickness of at least 2-3 mm, which corresponds to an ecst stenosis of 30% * written informed consent exclusion criteria: * patients with probable cardiac source of embolism (rhythm disorders, mitral valve stenosis, prolapse or calcification, mechanical cardiac valves, recent myocardial infarction, left ventricular thrombus, atrial myxoma, endocarditis, dilated cardiomyopathy, patent foramen ovale) or a clotting disorder * patients with evident other cause of neurological symptoms than carotid stenosis due to atherosclerotic disease (like demyelinating diseases, epilepsy, congenital brain disorders, aneurysms, fibromuscular dysplasia etc) * patients already scheduled for carotid endarterectomy or stenting. * severe co-morbidity, dementia or pregnancy * standard contra-indications for mri * patients who have a documented allergy to mri or ct contrast media * patients with renal clearance \< 30 ml/minute are not eligible to undergo contrast-enhanced mri * patients with renal clearance \< 60 ml/minute are not eligible to undergo mdct * patients who had a tia or minor stroke more than 3 months before inclusion

Keywords: plaque imaging